Ribonexus (previously Aglaia Therapeutics) and French pharmaceutical group Pierre Fabre signed an exclusive license agreement on a series of Pierre Fabre-patented small molecules targeting the eukaryotic translation initiation factor 4A (eIF4A). This target is highly expressed in a variety of solid and hematologic cancers, including melanoma, and associated with resistance to many current therapies.
Researchers at the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences have been awarded five grants from NCI in 2024, totaling $4.6 million.
